The	0	3	O
tyrosine	4	12	O
kinase	13	19	O
inhibitor	20	29	O
cediranib	30	39	B-Drug_or_compound
blocks	40	46	O
ligand	47	53	O
-	53	54	O
induced	54	61	O
vascular	62	70	B-Gene_or_gene_product
endothelial	71	82	I-Gene_or_gene_product
growth	83	89	I-Gene_or_gene_product
factor	90	96	I-Gene_or_gene_product
receptor	97	105	I-Gene_or_gene_product
-	105	106	I-Gene_or_gene_product
3	106	107	I-Gene_or_gene_product
activity	108	116	O
and	117	120	O
lymphangiogenesis	121	138	O
.	138	139	O

Solid	141	146	B-Pathological_formation
tumors	147	153	I-Pathological_formation
express	154	161	O
a	162	163	O
range	164	169	O
of	170	172	O
factors	173	180	O
required	181	189	O
to	190	192	O
sustain	193	200	O
their	201	206	O
growth	207	213	O
and	214	217	O
promote	218	225	O
their	226	231	O
dissemination	232	245	O
.	245	246	O

Among	247	252	O
these	253	258	O
are	259	262	O
vascular	263	271	B-Gene_or_gene_product
endothelial	272	283	I-Gene_or_gene_product
growth	284	290	I-Gene_or_gene_product
factor	291	297	I-Gene_or_gene_product
-	297	298	I-Gene_or_gene_product
A	298	299	I-Gene_or_gene_product
(	300	301	O
VEGF	301	305	B-Gene_or_gene_product
-	305	306	I-Gene_or_gene_product
A	306	307	I-Gene_or_gene_product
)	307	308	O
,	308	309	O
the	310	313	O
key	314	317	O
angiogenic	318	328	O
stimulant	329	338	O
,	338	339	O
and	340	343	O
VEGF	344	348	B-Gene_or_gene_product
-	348	349	I-Gene_or_gene_product
C	349	350	I-Gene_or_gene_product
,	350	351	O
a	352	353	O
primary	354	361	O
mediator	362	370	O
of	371	373	O
lymphangiogenesis	374	391	O
.	391	392	O

Small	393	398	O
molecule	399	407	O
tyrosine	408	416	B-Drug_or_compound
kinase	417	423	I-Drug_or_compound
inhibitors	424	434	I-Drug_or_compound
offer	435	440	O
the	441	444	O
potential	445	454	O
to	455	457	O
inhibit	458	465	O
more	466	470	O
than	471	475	O
one	476	479	O
kinase	480	486	O
and	487	490	O
impede	491	497	O
tumor	498	503	B-Pathological_formation
growth	504	510	O
by	511	513	O
multiple	514	522	O
mechanisms	523	533	O
.	533	534	O

However	535	542	O
,	542	543	O
their	544	549	O
potency	550	557	O
toward	558	564	O
individual	565	575	O
targets	576	583	O
can	584	587	O
vary	588	592	O
.	592	593	O

Cediranib	594	603	B-Drug_or_compound
(	604	605	O
RECENTIN	605	613	B-Drug_or_compound
;	613	614	O
AZD2171	615	622	B-Drug_or_compound
)	622	623	O
is	624	626	O
an	627	629	O
inhibitor	630	639	O
of	640	642	O
VEGF	643	647	B-Gene_or_gene_product
signaling	648	657	O
that	658	662	O
has	663	666	O
been	667	671	O
shown	672	677	O
in	678	680	O
experimental	681	693	O
models	694	700	O
to	701	703	O
prevent	704	711	O
VEGF	712	716	B-Gene_or_gene_product
-	716	717	I-Gene_or_gene_product
A	717	718	I-Gene_or_gene_product
-	718	719	O
induced	719	726	O
angiogenesis	727	739	O
and	740	743	O
primary	744	751	O
tumor	752	757	B-Pathological_formation
growth	758	764	O
,	764	765	O
yet	766	769	O
the	770	773	O
effects	774	781	O
of	782	784	O
cediranib	785	794	B-Drug_or_compound
on	795	797	O
VEGF	798	802	B-Gene_or_gene_product
receptor	803	811	I-Gene_or_gene_product
(	812	813	I-Gene_or_gene_product
VEGFR	813	818	I-Gene_or_gene_product
)	818	819	I-Gene_or_gene_product
-	819	820	I-Gene_or_gene_product
3	820	821	I-Gene_or_gene_product
-	821	822	O
mediated	822	830	O
endothelial	831	842	B-Cell
cell	843	847	I-Cell
function	848	856	O
and	857	860	O
lymphangiogenesis	861	878	O
are	879	882	O
unknown	883	890	O
.	890	891	O

To	892	894	O
better	895	901	O
understand	902	912	O
the	913	916	O
activity	917	925	O
of	926	928	O
cediranib	929	938	B-Drug_or_compound
against	939	946	O
VEGFR	947	952	B-Gene_or_gene_product
-	952	953	I-Gene_or_gene_product
3	953	954	I-Gene_or_gene_product
and	955	958	O
its	959	962	O
associated	963	973	O
signaling	974	983	O
events	984	990	O
compared	991	999	O
with	1000	1004	O
its	1005	1008	O
activity	1009	1017	O
against	1018	1025	O
VEGFR	1026	1031	B-Gene_or_gene_product
-	1031	1032	I-Gene_or_gene_product
2	1032	1033	I-Gene_or_gene_product
,	1033	1034	O
we	1035	1037	O
used	1038	1042	O
the	1043	1046	O
receptor	1047	1055	O
-	1055	1056	O
specific	1056	1064	O
ligands	1065	1072	O
VEGF	1073	1077	B-Gene_or_gene_product
-	1077	1078	I-Gene_or_gene_product
E	1078	1079	I-Gene_or_gene_product
and	1080	1083	O
VEGF	1084	1088	B-Gene_or_gene_product
-	1088	1089	I-Gene_or_gene_product
C156S	1089	1094	I-Gene_or_gene_product
.	1094	1095	O

In	1096	1098	O
human	1099	1104	B-Organism
endothelial	1105	1116	B-Cell
cells	1117	1122	I-Cell
,	1122	1123	O
cediranib	1124	1133	B-Drug_or_compound
inhibited	1134	1143	O
VEGF	1144	1148	B-Gene_or_gene_product
-	1148	1149	I-Gene_or_gene_product
E	1149	1150	I-Gene_or_gene_product
-	1150	1151	O
induced	1151	1158	O
phosphorylation	1159	1174	O
of	1175	1177	O
VEGFR	1178	1183	B-Gene_or_gene_product
-	1183	1184	I-Gene_or_gene_product
2	1184	1185	I-Gene_or_gene_product
and	1186	1189	O
VEGF	1190	1194	B-Gene_or_gene_product
-	1194	1195	I-Gene_or_gene_product
C156S	1195	1200	I-Gene_or_gene_product
-	1200	1201	O
induced	1201	1208	O
phosphorylation	1209	1224	O
of	1225	1227	O
VEGFR	1228	1233	B-Gene_or_gene_product
-	1233	1234	I-Gene_or_gene_product
3	1234	1235	I-Gene_or_gene_product
at	1236	1238	O
concentrations	1239	1253	O
of	1254	1256	O
less	1258	1262	O
than	1263	1267	O
/	1268	1269	O
=	1269	1270	O
1nmol	1270	1275	O
/	1275	1276	O
L	1276	1277	O
and	1278	1281	O
inhibited	1282	1291	O
activation	1292	1302	O
of	1303	1305	O
downstream	1306	1316	O
signaling	1317	1326	O
molecules	1327	1336	O
.	1336	1337	O

Additionally	1338	1350	O
,	1350	1351	O
cediranib	1352	1361	B-Drug_or_compound
blocked	1362	1369	O
VEGF	1370	1374	B-Gene_or_gene_product
-	1374	1375	I-Gene_or_gene_product
C156S	1375	1380	I-Gene_or_gene_product
-	1380	1381	O
induced	1381	1388	O
and	1389	1392	O
VEGF	1393	1397	B-Gene_or_gene_product
-	1397	1398	I-Gene_or_gene_product
E	1398	1399	I-Gene_or_gene_product
-	1399	1400	O
induced	1400	1407	O
proliferation	1408	1421	O
,	1421	1422	O
survival	1423	1431	O
,	1431	1432	O
and	1433	1436	O
migration	1437	1446	O
of	1447	1449	O
lymphatic	1450	1459	B-Cell
and	1460	1463	O
blood	1464	1469	B-Cell
vascular	1470	1478	I-Cell
endothelial	1479	1490	I-Cell
cells	1491	1496	I-Cell
.	1496	1497	O

In	1498	1500	O
vivo	1501	1505	O
,	1505	1506	O
cediranib	1507	1516	B-Drug_or_compound
(	1517	1518	O
6	1518	1519	O
mg	1520	1522	O
/	1522	1523	O
kg	1523	1525	O
/	1525	1526	O
d	1526	1527	O
)	1527	1528	O
prevented	1529	1538	O
angiogenesis	1539	1551	O
and	1552	1555	O
lymphangiogenesis	1556	1573	O
induced	1574	1581	O
by	1582	1584	O
VEGF	1585	1589	B-Gene_or_gene_product
-	1589	1590	I-Gene_or_gene_product
E	1590	1591	I-Gene_or_gene_product
-	1591	1592	O
expressing	1592	1602	O
and	1603	1606	O
VEGF	1607	1611	B-Gene_or_gene_product
-	1611	1612	I-Gene_or_gene_product
C156S	1612	1617	I-Gene_or_gene_product
-	1617	1618	O
expressing	1618	1628	O
adenoviruses	1629	1641	B-Organism
,	1641	1642	O
respectively	1643	1655	O
.	1655	1656	O

Cediranib	1657	1666	B-Drug_or_compound
(	1667	1668	O
6	1668	1669	O
mg	1670	1672	O
/	1672	1673	O
kg	1673	1675	O
/	1675	1676	O
day	1676	1679	O
)	1679	1680	O
also	1681	1685	O
blocked	1686	1693	O
angiogenesis	1694	1706	O
and	1707	1710	O
lymphangiogenesis	1711	1728	O
induced	1729	1736	O
by	1737	1739	O
adenoviruses	1740	1752	B-Organism
expressing	1753	1763	O
VEGF	1764	1768	B-Gene_or_gene_product
-	1768	1769	I-Gene_or_gene_product
A	1769	1770	I-Gene_or_gene_product
or	1771	1773	O
VEGF	1774	1778	B-Gene_or_gene_product
-	1778	1779	I-Gene_or_gene_product
C	1779	1780	I-Gene_or_gene_product
and	1781	1784	O
compromised	1785	1796	O
the	1797	1800	O
blood	1801	1806	B-Organism_substance
and	1807	1810	O
lymphatic	1811	1820	B-Multi-tissue_structure
vasculatures	1821	1833	I-Multi-tissue_structure
of	1834	1836	O
VEGF	1837	1841	B-Gene_or_gene_product
-	1841	1842	I-Gene_or_gene_product
C	1842	1843	I-Gene_or_gene_product
-	1843	1844	O
expressing	1844	1854	O
tumors	1855	1861	B-Pathological_formation
.	1861	1862	O

Cediranib	1863	1872	B-Drug_or_compound
may	1873	1876	O
,	1876	1877	O
therefore	1878	1887	O
,	1887	1888	O
be	1889	1891	O
an	1892	1894	O
effective	1895	1904	O
means	1905	1910	O
of	1911	1913	O
preventing	1914	1924	O
tumor	1925	1930	B-Pathological_formation
progression	1931	1942	O
,	1942	1943	O
not	1944	1947	O
only	1948	1952	O
by	1953	1955	O
inhibiting	1956	1966	O
VEGFR	1967	1972	B-Gene_or_gene_product
-	1972	1973	I-Gene_or_gene_product
2	1973	1974	I-Gene_or_gene_product
activity	1975	1983	O
and	1984	1987	O
angiogenesis	1988	2000	O
,	2000	2001	O
but	2002	2005	O
also	2006	2010	O
by	2011	2013	O
concomitantly	2014	2027	O
inhibiting	2028	2038	O
VEGFR	2039	2044	B-Gene_or_gene_product
-	2044	2045	I-Gene_or_gene_product
3	2045	2046	I-Gene_or_gene_product
activity	2047	2055	O
and	2056	2059	O
lymphangiogenesis	2060	2077	O
.	2077	2078	O

